H A R M S
First Choice
Acalabrutinib
Benefit Score:
0
Burden Score:
25
Harms Score:
0
Second Choice
Venetoclax + Obintuzumab
Benefit Score:
0
Burden Score:
75
Harms Score:
0
Third Choice
Chemotherapy + Rituximab
Benefit Score:
0
Burden Score:
75
Harms Score:
0
Third Choice
Second Choice
First Choice
B E N E F I T S
